2015 American Society of Clinical Oncology Annual Meeting*

Investigators found 3 distinct stem cell phenotypes in AML with no leukemia-free survival at 2 years in those with ALDHhigh phenotype without a bone marrow transplant.

Inheritance of a lower number of activating KIR genes in NK cells associated with increased risk of developing high-risk MDS.

Doses of gilteritinib ≥ 80 mg showed an ORR of 58% in patients with relapsed/refractory AML and the FLT3 mutation.

CD19-targeted 19-28ζ CAR T-cell therapy produced a high CR rate in adult patients with relapsed/refractory ALL.

Results of an open-label phase III trial investigating the safety and efficacy of adding idelalisib to ofatumumab in pretreated CLL.

Results of a prospectively designed meta-analysis of a new surrogate endpoint that may expedite patient access to effective new therapies.

In patients with previously untreated high-intermediate–risk or high-risk DLBCL, brentuximab vedotin + R-CHOP was associated with a response rate of 80%.

Results from a randomized phase III trial investigating the addition of the mAB elotuzumab to lenalidomide and dexamethasone in patients with relapsed/refractory MM.

Results from the first head-to-head phase III trial comparing 2 proteasome inhibitors in multiple myeloma.

Phase II study evaluating induction regimen of KRd, followed by ASCT, KRd consolidation, and maintenance in newly diagnosed multiple myeloma.

In this continuation of a phase I/II trial, the optimized dose and schedule of panobinostat and carfilzomib was associated with promising responses in relapsed/refractory multiple myeloma.

Overall response rates of 50% in DLBCL and 100% in follicular lymphoma; all CRs maintained as of last analysis.

Retrospective analysis suggests that subsets of patients with FL may receive suboptimal doses of rituximab.

Sagar Lonial, MD; Farhad Ravandi, MD; Jeff P. Sharman, MD; and Julie M. Vose, MD, MBA, discuss the clinical relevance of key findings in hematologic malignancies presented at the 2015 American Society of Clinical Oncology annual meeting.

Sagar Lonial, MD Farhad Ravandi, MD Jeff P. Sharman, MD Julie M. Vose, MD, MBA Physicians: maximum of 2.75 AMA PRA Category 1 Credits™ Released: August 25, 2015 Expired: August 24, 2016

In this downloadable slideset, Sagar Lonial, MD, Farhad Ravandi, MD, Jeff P. Sharman, MD, and Julie M. Vose, MD, MBA, discuss the clinical relevance of key findings in hematologic malignancies presented at the 2015 American Society of Clinical Oncology annual meeting.

New phase III results from the HELIOS trial of ibrutinib plus BR in previously treated CLL/SLL.

In this phase III study, pacritinib demonstrated significantly reduced total symptom scores and improved overall survival.

The obinutuzumab-containing regimen was associated with a significant reduction in the risk of progression or death compared with bendamustine alone in patients with rituximab-refractory indolent NHL.

In this population of patients who had received a median of 5 prior therapies over 5 years and were refractory to most available agents, daratumumab was associated with an ORR of 29%; no patients discontinued due to adverse events.